Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome
Genes · 2024
DOI: 10.3390/genes15101248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Angeli Joy B Barretto und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical, Biological, and Materials Engineering and Sciences, Mapúa University, Manila City 1002, Philippines. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Gene Expression Regulation, Neoplastic, Transcriptome. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC), representing 85% of lung cancer cases, is characterized by its heterogeneity and progression through distinct stages. This study applied Weighted Gene Co-expression Network Analysis (WGCNA) to explore the molecular mechanisms of NSCLC and identify potential therapeutic targets. Gene expression data from the GEO database were analyzed across four NSCLC stages (NSCLC1, NSCLC2, NSCLC3, and NSCLC4), with the NSCLC2 dataset selected as the reference for module preservation analysis. WGCNA identified eight highly preserved modules—Cyan, Yellow, Red, Dark Turquoise, Turquoise, White, Purple, and Royal Blue—across datasets, which were enriched in key pathways such as “Cell cycle” and “Pathways in cancer”, involving processes like cell division and inflammatory responses. Hub genes, including PLK1, CDK1, and EGFR, emerged as critical regulators of tumor proliferation and immune responses. Estrogen receptor ESR1 was also highlighted, correlating with improved survival outcomes, suggesting its potential as a prognostic marker. Signature-based drug repurposing analysis identified promising therapeutic candidates, including GW-5074, which inhibits RAF and disrupts the EGFR–RAS–RAF–MEK–ERK signaling cascade, and olomoucine, a CDK1 inhibitor. Additional candidates like pinocembrin, which reduces NSCLC cell invasion by modulating epithelial-mesenchymal transition, and citalopram, an SSRI with anti-carcinogenic properties, were also identified. These findings provide valuable insights into the molecular underpinnings of NSCLC and suggest new directions for therapeutic strategies through drug repurposing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical, Biological, and Materials Engineering and Sciences, Mapúa University, Manila City 1002, Philippines.
- School of Graduate Studies, Mapúa University, Manila City 1002, Philippines.
- Department of Food Science, National Taiwan Ocean University, Keelung 20224, Taiwan.
- Department of Biology, School of Health Sciences, Mapúa University, Makati City 1203, Philippines.
ORCID-Profile: Po-Wei Tsai
Zitieren
APA
Barretto, A. J. B., Orda, M. A., Tsai, P. W., & Tayo, L. L. (2024). Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome. Genes. https://doi.org/10.3390/genes15101248
Vancouver
Barretto AJB, Orda MA, Tsai PW, Tayo LL. Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome. Genes. 2024. doi:10.3390/genes15101248
BibTeX
@article{Barretto2024,
author = {Barretto, Angeli Joy B and Orda, Marco A and Tsai, Po-Wei and Tayo, Lemmuel L},
title = {Analysis of Modular Hub Genes and Therapeutic Targets across Stages of Non-Small Cell Lung Cancer Transcriptome},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15101248}
}
EUVIMED